|Report from the Annual General Meeting of Immunicum AB (publ) on 4 May 2021|
|By: GlobenewsWire - 04 May 2021||Back to overview list
4 May 2021
Report from the Annual General Meeting of Immunicum AB (publ) on 4 May 2021
At the annual general meeting (the “AGM”) of Immunicum AB (publ), reg. no 556629-1786, (the “Company”), on 4 May 2021 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the AGM and the complete proposals, which have previously been published and are available on the Company’s website, www.immunicum.com.
Adoption of the balance sheet and income statement, disposition regarding the Company’s results and discharge from liability
The AGM resolved that the Company’s accumulated losses shall be appropriated so that SEK 106,307,963 is settled against the share premium reserve and that the remaining SEK 717,815,244 is carried forward and that no dividends shall be paid for the financial year 2020.
The AGM also discharged the board members and the managing director from liability for the financial year 2020.
The AGM resolve to approve the board of directors’ remuneration report for 2020.
Remuneration to the board of directors and auditor
The AGM decided that remuneration to the auditor shall be paid according to approved invoice.
Election of board members and auditor
For the period until the end of the next annual general meeting the AGM re-elected the present board members Sven Andreasson, Dharminder Chahal, Andrea van Elsas, Christine Lind and Helén Tuvesson. Hans Preusting was elected as new board member. Charlotte Edenius and Steven Glazer have requested to not be re-elected. Christine Lind was re-elected as chairman of the board of directors.
The AGM resolved to re-elect the registered audit firm Ernst & Young AB as auditor for the period until the end of the next annual general meeting. Ernst & Young AB has informed that Anna Svanberg will remain as auditor in charge.
Resolution regarding principles for the appointment and assignment of the nomination committee
Resolution regarding amendment of the articles of association
Resolution regarding amendment of guidelines for remuneration to senior executives
Resolution regarding performance based LTI 2021/2024
Each employee stock option and restricted share unit entitles the holder the right to subscribe for one (1) new share in the Company during the period commencing on 1 September 2024 up to and including 31 October 2024. The subscription price when exercising the employee stock option shall be equivalent to 140 per cent of the volume-weighted average price paid during the period commencing at 5 May 2021 up until and including 19 May 2021 of the noted paid prices (according to Nasdaq Stockholm’s official rating list) for shares in the Company. The subscription price when exercising the restricted share unit shall correspond to the quota value of the shares in the Company. The employee stock options and restricted share units are allotted free of charge to the participants.
Authorization for the board of directors to decide on new share issues and issues of warrants and/or convertibles
The information in this press release is information that Immunicum AB (publ) is obliged to disclose pursuant to Nasdaq Stockholm’s Rule Book for Issuers. The information was released for public disclosure through the agency of the contact persons set out below 12:00 CET on 4 May, 2021.
FOR MORE INFORMATION, PLEASE CONTACT:
Eva Mulder and Sophia Hergenhan
ABOUT IMMUNICUM AB (PUBL)
Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival outcomes and quality of life for a broad population of cancer patients. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com
Copyright 2021 GlobenewsWire
|Back to overview list|